Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRTD16)

Drug Name
talinolol Drug Info
Synonyms
Talinolol; 57460-41-0; Cordanum; Racemic talinolol; 1-(4-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)PHENYL)-3-CYCLOHEXYLUREA; Talinolol [INN]; (+-)-Talinolol; Talinololum [INN-Latin]; 38649-73-9; 1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane; Talinolol (INN); (+-)-N-Cyclohexyl-N'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea; NCGC00164542-01; 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol
Cross-matching ID
PubChem CID
68770
ChEBI ID
CHEMBL152067
CAS Number
CAS 57460-41-0
TTD Drug ID
D05JKG
VARIDT Drug ID
DR00401
INTEDE Drug ID
DR1527

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Melanogenesis 2.06 0.00e+0 74/101 (73.27%) GNAI1;TYRP1;GNAS;...
Gap junction 1.98 1.03e-2 72/88 (81.82%) GNAI1;GJA1;GNAS;...
Parathyroid hormone synthesis, secretion and action 1.95 1.37e-2 98/106 (92.45%) GNAI1;PDE4B;GNAS;...
Regulation of lipolysis in adipocytes 1.93 1.80e-2 52/55 (94.55%) GNAI1;GNAS;NPY;...
Steroid biosynthesis 1.88 1.85e-2 19/20 (95%) MSMO1;CYP51A1;FDFT1;...
Platelet activation 1.82 2.57e-2 106/124 (85.48%) GNAI1;COL1A2;FGG;...
Circadian entrainment 1.78 3.52e-2 85/97 (87.63%) GNAI1;PER2;PER3;...
Renin secretion 1.75 3.98e-2 61/69 (88.41%) GNAI1;GNAS;AQP1;...
Cushing syndrome 1.73 4.22e-2 125/155 (80.65%) GNAI1;GNAS;PBX1;...
Morphine addiction 1.70 4.95e-2 80/91 (87.91%) GNAI1;PDE4B;GNAS;...
Oxytocin signaling pathway 1.70 4.79e-2 128/154 (83.12%) GNAI1;GNAS;PPP1CB;...
Nitrogen metabolism 1.70 4.42e-2 16/17 (94.12%) CPS1;GLUL;CA2
Glycosaminoglycan degradation -2.12 0.00e+0 19/19 (100%) GLB1;HEXA;HYAL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 3.33uM 24H